AFJKR shows severe financial deterioration with operating losses expanding 36x to -$1.1M, current assets collapsing 95% to just $30K, and stockholders' equity plunging deeper into negative territory to -$1.5M.
This blank check company (SPAC) incorporated in 2023 is burning through cash rapidly while seeking acquisitions in biopharmaceutical and medical technology sectors. The dramatic reduction in share count from 9.0M to 6.1M shares combined with collapsing current assets and exploding liabilities suggests significant financial stress that could impair the company's ability to complete its acquisition mission.
The financial picture reveals a company in severe distress, with operating losses exploding from -$28K to -$1.1M while current assets collapsed by 95% to just $30K and current liabilities surged 32x to $817K. Despite reporting positive net income of $2.6M (likely from non-operating gains), the underlying operational deterioration combined with negative stockholders' equity of -$1.5M signals a company struggling to maintain viability. The dramatic reduction in both assets and outstanding shares suggests potential redemptions or other capital structure stress that threatens the SPAC's ability to execute its business combination strategy.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Current liabilities surged 3188.9% — significant near-term obligations; verify ability to meet short-term debt.
Net income grew 1389.1% — bottom-line growth signals improving overall business health.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Liabilities grew 110.8% — significant increase in debt or obligations, assess impact on financial flexibility.
Current assets declined 94.8% — monitor working capital adequacy and short-term liquidity.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →